Large-scale lung cancer screening (Study 2021-02)

Record ID 32018005494
English
Authors' objectives: According to the most recent figures, nearly 8900 new lung cancers are diagnosed every year in Belgium, and about 5850 patients die from the disease. As the second most common cancer in men and the third most common in women, lung cancer has a significant impact on the health care system and on society as a whole. In individuals with an increased risk profile, it can be detected – and, hence, treated – at an early stage through medical imaging with a low-dose CT scan. This screening greatly improves prognosis and makes it possible to avoid more severe, less effective treatments. However, as with any screening programme, there are also potential drawbacks, such as false-positive results and overdiagnosis. This study aims to investigate the added value of a potential screening programme for lung cancer in Belgium. This Health Technology Assessment (HTA) will allow us to weigh its benefits against its drawbacks. Specifically, we will evaluate: - Effectiveness and safety - Economic aspects, in terms of cost-effectiveness and budget impact Ethical and organisational aspects of a potential lung cancer screening programme will also be discussed
Details
Project Status: Ongoing
Anticipated Publish Date: 2024
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Belgium
MeSH Terms
  • Lung Neoplasms
  • Tomography, X-Ray Computed
  • Mass Screening
  • Cost-Effectiveness Analysis
  • Early Detection of Cancer
Keywords
  • lung cancer
  • CT scan
  • Screening programme
Contact
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be
Copyright: <p>Belgian Health Care Knowledge Centre (KCE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.